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Regulatory interactions between inducible nitric oxide synthase and
eicosanoids in glomerular immune injury. In a rat model of glomerular
immune injury induced by administration of anti-glomerular basement
membrane antibody and resembling human rapidly progressive glomeru-
lonephritis, we explored whether activation of inducible nitric oxide
synthase (iNOS) regulates synthesis of eicosanoids originating from
cyclooxygenation or lipoxygenation of arachidonic acid. At early stages (24
hr) of injury, inhibition of iNOS using the selective inhibitor L-N6-(1-
iminoethyl) lysine (L-NIL) at doses sufficient to reduce urinary excretion
of nitrate/nitrite, reduced glomerular synthesis of the prostaglandins PGE2
and PGI2, but had no effect on that of thromboxane A2 (TxA2). The
syntheses of 5-hydroxyeicosatetraenoic acid (HETE), 15-HETE and leu-
kotriene B4 (LTB4) were also reduced. That of 12-HETE remained
unchanged. We also explored the effect of arachidonate cyclooxygenation
and lipoxygenation eicosanoids on iNOS expression. Administration of the
cyclooxygenase (COX) inhibitor, indomethacin, at doses sufficient to
inhibit glomerular prostaglandin synthesis, increased iNOS mRNA levels
in glomeruli. Administration of the 5-lipoxygenase (5-LO) inhibitor,
MK-0591, at doses sufficient to inhibit glomerular LTB4 synthesis also
increased iNOS mRNA. The effect of 5-LO inhibition on iNOS expression
was more pronounced than that of COX inhibition. In nephritic animals
given the iNOS inhibitor, L-NIL, or indomethacin proteinuria worsened.
In those given the 5-lipoxygenase inhibitor there was no change in urine
protein excretion. These observations point to regulatory interactions
between the arachidonic acid and the L-arginine:NO pathways in glomer-
ulonephritis. These interactions are of importance in considering antiin-
flammatory strategies based on inhibition of iNOS or of specific eico-
sanoids.
Two proinflammatory events occurring in the glomerulus in the
course of antibody or cell-mediated immune injury are: (a)
cyclooxygenation and lipoxygenation of arachidonic acid to pros-
taglandins (PG), thromboxane (Tx), leukotrienes (LT) and hy-
droxyeicosatetraenoic acids (HETE), and (b) generation of nitric
oxide (NO) from L-arginine via the inducible form of nitric oxide
synthase (iNOS) [1, 2]. Generation of NO as a result of iNOS
activation can be sustained and of high output [3]. Evidence,
obtained mostly in vitro, indicates that binding of NO to the
heme-iron of cyclooxygenase or the non-heme iron of lipoxygen-
ases may modulate activity of these enzymes [4, 5]. In vitro
evidence also indicates that eicosanoids may modulate the expres-
sion of iNOS. Thus, PGE2 down-regulates iNOS expression in
cultured glomerular mesangial cells stimulated with cytokines [6].
Although in glomerular immune injury both the arachidonic acid
pathway towards synthesis of proinflammatory eicosanoids, and
the L-arginine pathway towards generation of NO become acti-
vated, evidence that regulatory interactions do occur between the
two pathways following onset of injury is lacking. Demonstration
that such interactions do occur is of apparent importance in our
understanding of the pathobiology of glomerulonephritis and in
considering anti-inflammatory strategies based on inhibition of
iNOS or of specific eicosanoids. The present studies assess these
interactions in a model of rapidly progressive glomerulonephritis.
METHODS
Development of renal immune injury
A model of accelerated glomerulonephritis induced in the rat
by administration of antibody against rat glomerular basement
membrane (GBM) was employed. Male Sprague-Dawley rats
weighing 180 to 200 g were immunized intraperitoneally with 1 mg
rabbit IgG emulsified in complete Freund’s adjuvant and given in
a total volume of 0.5 ml. Five days following this immunization,
animals received an injection of a subnephritogenic dose of rabbit
immune serum raised against rat particulate GBM prepared as
previously described [7]. The dose of immune serum was 0.15
ml/100 g body wt and this amount was insufficient by itself to
cause significant proteinuria when given to rats not immunized
with rabbit IgG (subnephritogenic). Prior to intravenous injection,
the rabbit anti-rat GBM immune serum was heat inactivated and
filtered through 1.2 mm filters. Control animals were preimmu-
nized with rabbit IgG in complete Freund’s adjuvant and subse-
quently given an intravenous injection of non-immune rabbit
serum. This protocol of induction of glomerular immune injury
results in rapid onset of glomerular cell proliferation, crescent
formation and scarring [8]. Studies were performed 24 hours
following injection of the anti-rat GBM serum or the non-immune
rabbit serum. Prior to sacrifice, animals were placed in metabolic
cages for urine collection to assess urinary protein excretion.
Upon completion of this collection, animals were nephrectomized
in order to isolate glomeruli by sieving of finely minced cortex as
previously described [1]. Glomerular preparations of 95 to 98%
purity were routinely obtained. Renal cortical sections were
processed for light and immunofluorescence microscopy studies
to assess the extent of glomerular injury (proliferative nephritis),
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as well as the extent of infiltration of glomeruli by activated
macrophages and platelets. The extent of macrophage infiltration
was assessed by staining for the rat monocyte-macrophage anti-
genic marker, ED1, and enumerating ED1 positive cells per
glomerulus. An FITC-conjugated anti-ED1 antibody (Serotec,
Westbury, NY, USA) was employed at a dilution of 1:50 in
phosphate buffered saline (PBS). Sections of at least 25 to 30
glomeruli of a cross sectional profile greater than 80% of the
maximum glomerular diameter (103 m) were examined and ED1
positive cells were enumerated. Results were expressed as ED1
(1) cells per glomerulus. The extent of intraglomerular platelet
deposition was assessed using an FITC-conjugated anti-platelet
antibody (Serotec) employed at a dilution of 1:250 in PBS.
Inhibition of inducible nitric oxide synthase and of eicosanoids
We and others have previously shown that in the model of
anti-GBM antibody induced injury there is enhanced synthesis of
arachidonic acid cyclooxygenation and lipoxygenation eicosanoids
in isolated glomeruli, and also enhanced expression of iNOS and
generation of nitric oxide [9–11]. Of the various eicosanoids, the
most abundantly synthesized are PGE2, PGI2, TxA2, 5-HETE,
12-HETE and LTB4 [9, 10]. Peak synthesis of these eicosanoids
and peak expression of iNOS occurs 24 hours following onset of
anti-GBM antibody-mediated injury [9–11]. Therefore, we chose
this time point as most suitable to assess the impact of iNOS
inhibition on eicosanoid synthesis, and the impact of eicosanoid
inhibition on iNOS expression. We and others have also shown
that activated macrophages infiltrating glomeruli following onset
of immune injury account to a significant extent both for the
origin of the aforementioned eicosanoids and for the enhanced
expression of iNOS and generation of NO in isolated glomeruli [1,
2]. It is, therefore, important to assess the impact of the pharma-
cologic inhibitors employed (see below) on the extent of macro-
phage infiltration in glomeruli. This was assessed by enumerating
ED1 (1) cells in glomerular sections as described above.
To inhibit iNOS, the selective inhibitor L-N6-(1-iminoethyl)
lysine (L-NIL) [12] was used (source: Dr. Mark G. Currie, The
Monsanto Co., St. Louis, MO, USA). This inhibitor has an IC50 of
3.3 mM for macrophage iNOS compared to an IC50 of 92 mM for
rat brain constitutive NOS indicating that L-NIL is 28-fold more
selective for inducible NOS. We employed doses and modes of
administration that were previously shown to be effective in
inhibiting iNOS-derived NO in other models of inflammation
[13]. In our studies, 15 mg/kg of L-NIL was injected in the tail vein
30 minutes prior to injection of the anti-rat GBM immune serum.
Eight hours following injection of the immune serum, the same
dose of L-NIL was repeated. This protocol resulted in reduction
of urinary NO excretion (measured as nitrite/nitrate, see below).
To inhibit cyclooxygenase (COX), the well established inhibi-
tor, indomethacin, was employed. A dose of 3 mg/kg was given
intravenously one hour before injection of the anti-GBM serum.
In pilot experiments, this dose inhibited synthesis of PGE2 in
glomeruli isolated 24 hours following administration of immune
serum.
To inhibit the arachidonate 5-lipoxygenase, we employed the
5-lipoxygenase activating protein (FLAP) inhibitor, MK-0591
(source: Dr. Anthony Ford-Hutchinson. Merck-Frosst, Dorval,
Quebec, Canada). The efficacy and selectivity of this inhibitor in
blocking glomerular synthesis of arachidonate 5-lipoxygenation
products (LTB4) following immune injury was established in our
previous studies using the anti-Thy 1 antibody-mediated injury
model [14]. Eight mg/kg of MK-0591 was dissolved in methylcel-
lulose and given through a nasogastric tube one hour before
injection of the anti-GBM antibody. In pilot experiments this dose
inhibited glomerular LTB4 from 3.6 6 0.6 ng per mg glomerular
protein in glomeruli of rats (N 5 3) given anti-GBM serum alone,
to 0.43 6 0.04 in glomeruli of rats (N 5 3) given anti-GBM serum
preceeded by administration of MK-0591.
Assessment of glomerular eicosanoid synthesis
This was assessed using methods of high pressure liquid chro-
matography (HPLC) and radioimmunoassay as we previously
described [10]. Isolated glomeruli were incubated under continu-
ous agitation in 1.5 ml of serum-free culture medium (RPMI-
1640) at 37°C for 30 minutes. At the end of this incubation, 500
mL of the incubation medium was removed for assay of PGE2,
6-keto-PGF1a (the stable metabolite of PGI2) and TxB2 (the
stable metabolite of TxA2) using established radioimmunoassay
methods as we previously reported [9]. Subsequently, glomeruli
were incubated for another 45 minutes in the presence of 1 mM of
the calcium ionophore A12387. The presence of the calcium
ionophore optimizes detection of hydroxyeicosatetraenoic acids
(HETE) and the leukotrienes, as arachidonate is inefficiently
metabolized via the lipoxygenase pathways in glomeruli [9, 15]. At
completion of this incubation, the glomerular preparation was
mixed with three volumes of ethanol. The ethanolic mixture was
placed under prolonged vigorous agitation at 4°C, and, following
centrifugation to pellet denatured glomerular proteins and debris,
the ethanolic mixture was dried under vacuum. The extract was
reconstituted in 1 ml of HPLC solvent (see below) and injected
into an HPLC system for separation of leukotrienes and HETE.
The HPLC system consisted of two solvent delivery modules
(Hitachi), a gradient controller, a reverse-phase, 250 3 4.6 mm,
octadecylsilica, 5-mm column (Phenomenex, Torrence, CA,
USA), and a fraction collector. Elutions were performed at flow
rates of 1 ml/min. An initial isocratic phase (25 min) using 100%
solvent B was used to elute the leukotrienes. This was followed by
a gradient phase to generate 80% solvent B/20% solvent A over a
20 minutes period in order to elute HETE. Solvent A was HPLC
grade tetrahydrofurane. Solvent B consisted of tetrahydrofurane:
methanol:water containing 0.1% EDTA:acetic acid (25:45:0.1,
vol:vol). The pH of solvent B was adjusted to 5.5 using concen-
trated ammonium hydroxide. This elution method provided good
separation between LTC4, LTD4, LTB4, 15-HETE, 12-HETE,
and 5-HETE, which eluted in this order. Typical retention times
(min) of standards of these eicosanoids were as follows (N 5 4 to
6 runs): LTC4 5 10.48 6 0.10, LTD4 5 14.97 6 0.28, LTB4 5
21.44 6 0.16, 15-HETE 5 41.43 6 0.20, 12-HETE 5 44.22 6 0.51,
5-HETE 5 47.22 6 0.46. Leukotrienes were detected during the
isocratic phase at l 5 280 nm using an on-line variable wavelength
detector (Hitachi) interfaced with an integrator/printer plotter.
Hydroxyeicosatetraenoic acids (HETE) were detected during the
gradient phase at l 5 232 nm. Elution fractions were collected at
one minute intervals and those corresponding to retention times
of the aforementioned eicosanoids were dried under vacuum and
reconstituted in 600 ml of assay buffer for quantitation by radio-
immunoassay. Recoveries were estimated by “spiking” glomerular
preparations with [3H] LT or [3H]-HETE before the ethanol
extration step. Recoveries varied between 65 to 72%. Radioim-
munoassays for each leukotriene and HETE were performed
according to established methods we previously reported [8, 9].
Antibodies for LTC4 and LTB4 were a gift from Dr. Anthony
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Ford-Hutchinson, (Merck-Frosst, Canada). Antibody for 12-
HETE was a gift from Dr. Lawrence Levine (Brandeis University,
Waltham, MA, USA). Antibodies for 5-HETE and 15-HETE
were purchased from Amersham Corp. (Arlington Heights, IL,
USA).
Assessment of glomerular inducible nitric oxide synthase
expression
This was assessed using an RNase protection assay. As normal
rat glomeruli express iNOS [16], we generated a iNOS cDNA
probe from RNA isolated from normal rat glomeruli using the
method of polymerase chain reaction (PCR) and iNOS gene
specific primers defining a 222 bp fragment of a published
sequence [17]. This probe was used in a RNase protection assay.
To isolate glomerular total RNA, glomeruli from normal rats
were isolated by sieving as described above. The glomerular
isolate was then mixed with 3 ml of a mixture containing gua-
nidium isothiocyanate/phenol chloroform (RNA Stat-60; Tell-
Test Inc., Frenchwood, TX, USA). The ensuing suspension was
allowed at stand at room temperature for five minutes, and 0.2 ml
of 100% chloroform was added and mixed thoroughly. After
another five minutes at room temperature, the suspension was
centrifuged at 4°C for 20 minutes. Following phase separation, the
upper RNA containing aqeous phase was removed into a micro-
centrifuge tube and mixed with an equal volume of 100% isopro-
panol. The RNA was precipitated by incubating the isopropanol
mixture at 220°C overnight. The isopropanol-precipitated RNA
was then centrifuged at 12,000 g at 4°C for 20 minutes, and the
pellet was redissolved in 300 ml of RNase-free water and extracted
once with each of 300 ml of 100% water saturated phenol, 50%
water-saturated phenol/48% chloroform/2% isoamyl alcohol (25:
24:1), 96% chloroform/4% isoamyl alcohol (24:1). RNA was
subsequently precipitated with 75% ethanol and 0.3 M sodium
acetate at 280°C. RNA concentration and quality was assessed
spectrophotometrically at wavelengths 260 and 280 nm.
To perform reverse transcription, first strand cDNA was syn-
thesized using oligo-dT. One microgram of glomerular total RNA
was reverse-transcribed in a total volume of 10 ml at 37°C for two
hours in 13 reaction buffer (USB; 50 mM Tris-HCl, pH 8.3, 75 mM
KCl, 3 mM MgCl2, 10 mM DTT) which contained 10 U/ml
MMLV-reverse transcriptase (USB, Cleveland, OH, USA), 0.02
mg/ml oligo-dT (Promega, Madison, WI, USA), 2 U/ml RNasin
(Promega), and 0.5 mM of each dNTP. Reactions were stopped by
heating the mixtures at 68°C for five minutes.
Primers for rat iNOS were selected based on a published
sequence [17], and were designed using the PRIMER software
system (Scientific and Educational Software, Stateline, PA, USA).
All primers were customed synthesized by Operon (Operon
Technologies Inc., Alameda, CA, USA). The sense primer was
59-GCATGGAACAGTATAAGGCAAACA-39. The anti-sense
primer was 59-GTTTCTGGTCGATGTCATGAGCAA-39.
To perform PCR, 1 ml of undiluted reverse transcription
products was used in a total volume of 50 ml. The 13 reaction
buffer contained 50 mM KCl, 10 mM Tris-HCl, pH 9.0, 0.1%
Triton X-100, 1.5 mM MgCl2, 0.2 mM of each dNTP, 1 mM of both
sense and anti-sense primers and 0.02 U/ml Taq-polymerase
(Promega). The PCR cycline profile was: 1.5 minutes at 94°C, two
minutes at 57°C, and three minutes at 72°C. Thirty-five cycles
were carried out and followed by final extension at 72°C for an
additional 10 minutes. The PCR product was identified by dideoxy
sequencing using established methods. Inducible nitric oxide
synthase cDNA generated by PCR was subsequently cloned to a
PCR-script SK (1) vector (Strategene, La Jolla, CA, USA) using
established methods. The ligation product was subsequently used
for transformation of E. coli supercompetent cells (Strategene)
and generation of a large scale preparation of plasmids containing
iNOS cDNA using established methods.
The RNase protection assay involved three steps: (1) lineariza-
tion of the iNOS cDNA containing plasmid, generation of sense
and antisense probe for iNOS using T3 RNA and T7 RNA
polymerases, respectively, and labeling the probes with 32P. (2)
Hybridization: 25 mg of total glomerular RNA was mixed with 10
mg yeast transfer RNA and 100,000 cpm of probe and then
precipitated in 0.3 M ammonium acetate using absolute ethanol.
The pellet was dissolved in 20 ml hybridization buffer (Ambion)
and incubated at 45°C overnight. (3) RNase digestion: the reac-
tion consisted of 0.5 units of RNase A and 20 units of RNase T1
added to each hybridization tube.
In the RNase protection assay procedure, an internal reference
standard was used to ensure that the apparent differences in iNOS
mRNA among treatment groups were not due to inconsistencies
in the assay procedure. The internal standard was rat ribosomal
protein L19 mRNA. cDNA probes for L19 RNA were synthesized
using the reverse transcription/polymerase chain reaction meth-
ods employed for iNOS RNA as described above. Primers for rat
ribosomal protein L19 RNA were designed using the PRIMER 2
software system and on the basis of a published sequence
(JO265O) obtained from GENEMBL-BANK. The L19 sense was
59-AGCCTGTGACTGTCCATTCC-39, and the L19 anti-sense
was 59-TTGGTCTTAGACCTGCGAGC-39. The PCR product
generated was 345 bp. The L19 cDNA was subsequently cloned to
a PCR-script SK (1) vector and the ligation product was used for
transformation of E. coli supercompetent cells and for generation
of a large scale preparation of plasmids containing the L19 cDNA
using established methods. For use in the RNase protection assay,
anti-sense probe for L19 was generated using T3 RNA polymer-
ase and the L19 containing plasmid was linearized by HindIII.
Sense probe for L19 was generated by T7 polymerase and the L19
containing plasmid was linearized by SacI.
All RNase digestions were performed at 37°C for 35 minutes,
and RNA was precipitated by an RNase inactivation/precipitation
buffer (Ambion) at 20°C for 30 minutes. The RNA was centri-
fuged at 12,000 g at 4°C for 20 minutes and the pellet was loaded
on a 8 M 5% polyacrylamide gel. Electropheresis was performed at
250V for three hours, and the gel was exposed to X-ray film
overnight at 20°C.
Assessment of urine nitrite/nitrate excretion
Nitrite and nitrate are stable end products of the reaction of
NO with oxygen. Their measurement in biological fluids, including
urine, has been used as an index of NO production. In our studies,
presence of these breakdown products of NO in the urine was
measured as a means to assess the efficacy of systemic adminis-
tration of the iNOS inhibitor L-NIL to inhibit renal NO produc-
tion. Urine aliquots of 5 ml were used for these measurements.
Nitrate in these aliquots was converted to nitrite by the addition
of nitrate reductase (14 mU) and the reduced form of nicotin-
amide adenine dinucleotide phosphate (NADPH, 1 nmol) with
incubation for 10 minutes at room temperature. The reaction was
terminated by dilution with water and addition of diaminonaptha-
lene reagent (Griess reaction) [18]. Nitrite concentrations in the
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samples were determined fluorometrically with sodium nitrite
used as standard. All determinations were performed in duplicate
and results were expressed as nmol of nitrite/nitrate per mg urine
creatinine.
Experimental groups
Group 1. Rats immunized with rabbit IgG mixed in complete
Freund’s adjuvant, and injected intravenously with rabbit anti-rat
GBM immune serum five days later (N 5 9).
Group 2. Animals immunized with rabbit IgG mixed in com-
plete Freund’s adjuvant, and injected intravenously with non-
immune rabbit serum five days later (N 5 6).
Group 3. The iNOS inhibition was the same as in group 1,
except these animals received 15 mg/kg of the iNOS inhibitor
L-NIL intravenously 30 minutes prior to administration of the
anti-rat GBM serum and eight hours afterwards (N 5 10).
Group 4. The iNOS inhibition controls were same as in 3, except
these animals received non-immune rabbit serum instead of
anti-rat GBM immune serum (N 5 4).
Group 5. The cyclooxygenase inhibition was the same as in
group 1, except these animals received indomethacin 3 mg/kg
intravenously one hour prior to injection of the anti-GBM serum
(N 5 3), or before injection of the non-immune rabbit serum (N 5
3). In rats that received anti-GBM serum or anti-GBM serum 1
indomethacin, glomerular RNA was isolated from animals se-
lected on the basis of comparable degrees of proteinuria and
glomerular ED1 (1) cell counts. Isolates from each animal were
pooled to generate sufficient amounts of RNA to assess iNOS
expression by the RNase protection assay described above.
Group 6. The 5-lipoxygenase inhibition was the same as in
group 1, except these animals received 8 mg/kg of the 5-lipoxy-
genase activating protein inhibitor MK-0591 via a nasogastric tube
one hour prior to injection of the anti-GBM serum (N 5 3), or
prior to the non-immune rabbit serum (N 5 3). In animals that
received anti-GBM serum or anti-GBM serum 1 MK-0591,
glomerular RNA was isolated from animals selected based on
comparable degrees of proteinuria and glomerular ED1 (1) cell
counts. Isolates from each animal were pooled to generate
sufficient amounts of RNA to assess iNOS expression by the
RNase protection assay.
In all above groups glomerular eicosanoid synthesis or iNOS
expression was assessed 24 hours following administration of the
anti-GBM serum.
Statistical analyses
Glomerular eicosanoid synthesis was expressed as pg or ng of
specific eicosanoid per mg glomerular protein. Urinary protein
excretion was expressed as mg total protein/g creatinine. Urine
nitrite/nitrate excretion was expressed as nmol/mg urine creati-
nine. Data were expressed as mean 6 SE. Comparisons employed
t-test statistics for unpaired observations.
RESULTS
All animals developed glomerular lesions characteristic of
proliferative nephritis and had increased urinary protein excretion
at the point of study (24 hr following onset of immune injury). The
extent of proteinuria in the various treatment groups is shown in
Figure 1. In nephritic animals that received the iNOS inhibitor,
L-NIL, or the cyclooxygenase inhibitor indomethacin, urinary
protein excretion was significantly higher compared to animals
with nephritis that did not receive L-NIL or indomethacin. In
nephritic animals that received the 5-lipoxygenase inhibitor, MK-
0591, urinary protein excretion was no different than in animals
with nephritis that did not receive this inhibitor (Fig. 1).
The dose of the iNOS inhibitor, L-NIL, employed was sufficient
to reduce urinary nitrate/nitrite excretion in animals with anti-
GBM nephritis. Values (nmol nitrate/nitrite per mg creatinine)
were: controls 11 6 9; anti-GBM nephritis 95 6 4; L-NIL 1
anti-GBM nephritis 35 6 10. The effect of iNOS inhibition using
L-NIL on glomerular prostaglandin and thromboxane synthesis is
shown in Figure 2. Synthesis of PGE2, 6-keto-PGF1a and TxB2
were increased in glomeruli isolated from animals with immune
injury, the most pronounced increase being that of TxB2. In
glomeruli isolated from animals with immune injury that were
treated with L-NIL synthesis of PGE2 and 6-keto-PGF1a was
reduced. In contrast, synthesis of TxB2 remained unchanged.
Administration of L-NIL to control animals that received non-
immune rabbit serum had no effect on glomerular prostaglandin
and TxB2 synthesis (data not shown).
The effect of iNOS inhibition on glomerular leukotriene and
HETE synthesis is shown in Figures 3 and 4. In glomeruli isolated
from rats with immune injury there was enhanced synthesis of the
5-lipoxygenation eicosanoids 5-HETE and LTB4 but not LTC4
(Fig. 3). In animals with immune injury treated with the iNOS
inhibitor, L-NIL, glomerular synthesis of 5-HETE and LTB4 was
reduced. In glomeruli isolated from rats with immune injury, there
was also enhanced synthesis of the arachidonate 12- and 15-
lipoxygenation eicosanoids, 12- and 15-HETE (Fig. 4). Synthesis
of 15-HETE, but not that of 12-HETE, was reduced in glomeruli
of nephritic rats treated with the iNOS inhibitor, L-NIL. Admin-
istration of L-NIL to control animals that received non-immune
Fig. 1. Urinary protein excretion assessed 24 hours following onset of
immune injury in the various treatment groups. Protein excretion (as-
sessed as urine protein, UPr, to urine creatinine, UCr, ratio) was signifi-
cantly increased animals with immune injury treated with the inducible
nitric oxide synthase (iNOS) inhibitor, L-N6-(1-iminoethyl) lysine (L-
NIL), or the cyclooxygenase inhibitor, indomethacin (INDO) and the
5-lipoxygenase inhibitor, MK-0591 (MK). *P , 0.05 compared to control;
**P , 0.05 compared to anti-GBM injury.
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rabbit serum had no effect on glomerular HETE or LT synthesis
(data not shown).
Changes in glomerular iNOS mRNA levels, assessed by RNase
protection assay, in response to treatment with the 5-lipoxygenase
inhibitor, MK-0951, or the cyclooxygenase inhibitor, indometha-
cin, are shown in Figure 5A. In glomeruli from animals with
immune injury there was enhanced iNOS expression compared to
controls. In glomeruli isolated from animals with immune injury
that received MK-0951 or indomethacin, iNOS expression was
further enhanced. This effect was more pronounced in glomeruli
from animals treated with the 5-lipoxygenase inhibitor. In Figure
5B, the changes in iNOS mRNA levels in glomeruli isolated from
animals that received anti-GBM serum, anti-GBM serum plus
MK-0857 and anti-GBM serum plus indomethacin are shown in
parallel with levels of mRNA of the rat ribosomal protein L19
(internal standard) assessed in the same RNase protection assay
procedure. There were no differences in L19 mRNA levels
indicating that there were no apparent inconsistencies in the
RNase protection assay procedure.
Figure 6 shows the extent of platelet deposition in glomeruli of a
Fig. 2. Effect of inducible nitric oxide synthase (iNOS) inhibition using L-N6-(1-iminoethyl) lysine (L-NIL) on glomerular synthesis of prostaglandin
E2 (PGE2), 6- keto-PGF1a and thromboxane B2 (TxB2). Symbols are: (M) Control; (f) anti-GBM nephritis; (o) anti-GBM nephritis 1 L-NIL. *P ,
0.05 compared to control; **P , 0.05 compared to anti-GBM injury.
Fig. 3. Effect of inducible nitric oxide synthase
(iNOS) inhibition using L-N6-(1-iminoethyl)
lysine (L-NIL) on glomerular synthesis of the
arachidonate 5-lipoxygenase eicosanoids, 5-
hydroxyeicosatetraenoic acid (5-HETE),
leukotriene B4 (LTB4) and leukotriene C4
(LTC4). Symbols are: (M) Control; (f) anti-
GBM nephritis; (o) anti-GBM nephritis 1 L-
NIL. *P , 0.05 compared to control; **P ,
0.05 compared to anti-GBM injury.
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nephritic animal that received anti-GBM serum alone (Fig. 6A), and
an animal that received anti-GBM serum preceeded by administra-
tion of the iNOS inhibitor, L-NIL (Fig. 6B). Intraglomerular platelet
deposition in the animal treated with the iNOS inhibitor was more
pronounced.
Table 1 summarizes the effect of the iNOS inhibitor, L-NIL, the
cyclooxygenase inhibitor, indomethacin, and the 5-lipoxygenase
inhibitor MK-0951 on glomerular macrophage counts obtained by
enumerating ED1 (1) macrophages per glomerulus in 20 to 25
glomeruli in renal cortical sections obtained from representative
animals of each treatment group. There was a marked increase in
number of macrophages per glomerulus in glomeruli of animals
with anti-GBM antibody-induced injury compared to controls
(25 6 2.6 vs. 3.2 6 1.1). Treatment with L-NIL, indomethacin, or
MK-0591, did not significantly alter the extent of glomerular
macrophage infiltration. The extent of macrophage infiltration
was highest in glomeruli of animals that were treated with
indomethacin. However, this increment did not reach statistical
significance.
DISCUSSION
It is well established that in glomerular immune injury there is
enhanced cyclooxygenation of arachidonic acid towards prosta-
glandins and thromboxane, and lipoxygenation towards HETE
and leukotrienes in isolated glomeruli [1]. Recent observations
have established that there is also enhanced generation of NO
from L-arginine and that this is associated with enhanced expres-
sion of iNOS [2]. In the model of anti-GBM antibody induced
injury, both phenomena peak at early stages (24 hr) following
onset of injury [9–11]. Activated macrophages infiltrating glomer-
uli following deposition of anti-GBM antibody and complement
activation are a major source of eicosanoids, and also account for
the enhanced expression of iNOS and generation of NO in
isolated glomeruli [1, 2]. Moreover, as iNOS activation can result
in sustained generation of NO, coupling of NO with superoxide
may occur thereby generating peroxynitrite, although definitive
evidence that peroxynitrite is formed in glomeruli following
immune injury is lacking. By virtue of its affinity for iron contain-
ing substrates, NO generated as a result of NOS activation can
target cyclooxygenase and lipoxygenases of which the former
contains heme-associated iron while the latter contain non-heme
iron [5]. Binding of NO to these enzymes may alter their activity
thereby regulating eicosanoid synthesis. Evidence for this effect is
based on in vitro and ex vivo studies [19], which demonstrated that
NO and peroxynitrite can stimulate cyclooxygenase activity to-
wards synthesis of prostaglandins. Proposed mechanisms for this
effect include: (a) NO binding to the heme-iron center of
cyclooxygenase [4], (b) NO promotes formation of nitrosothiols
on cystein residues of cyclooxygenase located in its catalytic
domain with subsequent alterations in secondary structure [20],
(c) peroxynitrite, in its function as an inorganic hydroperoxide, is
a potential substrate for the peroxidase activity of prostaglandin H
synthase and an activator of this enzyme’s cyclooxygenase activity
[21]. Using electron paramagnetic resonance spectroscopy, inves-
tigators have demonstrated that NO can also bind to the non-
heme iron of lipoxygenase (shown for soybean 15-lipoxygenase)
[22]. Evidence that NO can regulate mammalian lipoxygenase
activity is lacking.
The question whether NO generated in the course of glomer-
ular immune injury regulates synthesis of arachidonate cyclooxy-
genation and lipoxygenation eicosanoids is of major importance.
For example, the demonstration that generation of NO “drives”
synthesis of proinflammatory eicosanoids in the course of injury
would enhance our understanding of the biology of glomerulone-
phritis and result in novel therapeutic strategies aiming at inhibi-
tion of iNOS-derived NO or at dual inhibition of iNOS and of
specific proinflammatory eicosanoids. The model of anti-GBM
antibody mediated injury is uniquely suitable to test this hypoth-
esis. This is because in this model the arachidonic acid and the
L-arginine:NO pathways become coactivated, and the pattern and
temporal relationship of their activation is known [9–11]. To
assess the effect of iNOS-derived NO on glomerular eicosanoid
synthesis, we used the selective iNOS inhibitor L-NIL. We chose
this inhibitor because of: (a) good selectivity towards iNOS (it has
an IC50 of 3.3 mM for iNOS compared to 92 mM for constitutive
NOS), (b) lack of an effect on activity of purified cyclooxygenase
[23], and (c) demonstrated efficacy to inhibit iNOS in other
models of inflammation [13].
When used in doses sufficient to reduce urinary nitrite/nitrate
excretion, L-NIL reduced glomerular synthesis of PGE2 and
6-keto-PGF1a without an effect on synthesis of TxB2 (Fig. 4). The
inhibitory effect of L-NIL on PGE2 and PGI2 synthesis is consis-
tent with the observation that NO stimulates cyclooxygenase
activity. However, one would also expect a reduction in glomer-
ular TxA2 synthesis. This eicosanoid remained unchanged (Fig. 4).
The reason for this is unclear. Glomerular TxA2 originates to a
significant extent from platelets aggregating within the glomerular
capillary following onset of immune injury. As NO prevents
platelet aggregation [3], one possible explanation is that the
enhanced intraglomerular platelet aggregation (shown in Fig. 6),
which may have occurred as a result of inhibition of iNOS-derived
Fig. 4. Effect of inducible nitric oxide synthase (iNOS) inhibition using
L-N6-(1-iminoethyl) lysine (L-NIL) on glomerular synthesis of the ara-
chidonate 12- and 15-lipoxygenase eicosanoids, 12-HETE and 15-HETE.
Symbols are: (M) Control; (f) anti-GBM nephritis; (o) anti-GBM
nephritis 1 L-NIL. *P , 0.05 compared to control; **P , 0.05 compared
to anti-GBM injury.
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NO in animals with immune injury, resulted in enhanced throm-
boxane release. This may have masked the reduction in glomer-
ular TxA2 levels expected as a result of inhibition of cyclooxygen-
ase activity due to reduced iNOS-derived NO.
With respect to synthesis of arachidonate lipoxygenation eico-
sanoids, iNOS inhibition had a significant effect on glomerular
synthesis of 5-lipoxygenation eicosanoids (5-HETE and LTB4)
and on arachidonate 15-lipoxygenation (synthesis of 15-HETE)
(Fig. 5). 12-HETE synthesis remained unchanged. These obser-
vations indicate that iNOS-derived NO stimulates 5-lipoxygenase
and 15-lipoxygenase. It is not clear why an effect of 12-HETE
synthesis could not be demonstrated. One explanation is that NO
binding to 12-lipoxygenase may have no effect on activity of this
lipoxygenase. Studies using electron paramagnetic resonance
spectroscopy have demonstrated bond formation between NO and
the non-heme iron of 15-lipoxygenase [22]. This reaction may oxidize
the iron moiety from the ferrous to the ferric state thereby activating
the enzyme. Similar studies for mammalian 12-LO are lacking.
Both cyclooxygenase and 5-lipoxygenase inhibition enhanced
iNOS expression (steady-state mRNA levels) in glomeruli isolated
from rats with anti-GBM antibody injury that received these
inhibitors. This occurred without a significant change in the extent
of glomerular infiltration by activated macrophages (Table 1). We
assessed changes in the extent of glomerular macrophage infiltra-
tion because it is mainly in these cells that iNOS localizes
following glomerular immune injury [2]. Therefore, changes in
iNOS expression in isolated glomeruli must take into consider-
ation changes in the extent of glomerular macrophage infiltration
in response to the pharmacologic manipulations employed (cyclo-
oxygenase and 5-lipoxygenase inhibition). The enhanced iNOS
expression in response to cyclooxygenase inhibition is consistent
with the observation that cyclooxygenase products, in particular
PGE2, negatively modulate induction of NOS [6]. The enhanced
iNOS expression in response to 5-lipoxygenase inhibition points to
arachidonate 5-lipoxygenation eicosanoids, that is, 5-HETE and
LTB4, as negative modulators of iNOS expression in glomerular
immune injury.
Both iNOS inhibition using L-NIL and cyclooxygenase inhibi-
tion using indomethacin worsened proteinuria in animals with
immune injury (Fig. 2). The effect of iNOS inhibition on protein-
uria can be explained on the basis of the hemodynamic impact of
reduced NO synthesis. The renal hemodynamic consequences of
NO synthesis inhibition in the model of anti-GBM antibody
induced glomerulonephritis were previously assessed using clear-
ance and micropuncture studies [24]. In these studies it was shown
that NO synthesis inhibition results in elevations in afferent and
efferent arteriolar resistances and increases net transcapillary
hydraulic pressure (DP). The increase in DP offsets the fall in
glomerular plasma flow rate and ultrafiltration coefficient, Kf,
thereby preserving GFR. These changes in glomerular hemody-
namics, in particular the elevated intracapillary pressure, resulted
in increased urinary protein excretion in animals with anti-GBM
injury in which NO synthesis was inhibited using a non-selective
NOS inhibitor [24].
Inducible nitric oxide synthase (iNOS) expression in solid
organs has been proposed to be cytoprotective by preventing
microthrombosis and oxygen radical-mediated injury [25]. If this
cytoprotective effect applies in glomerular immune injury, iNOS
inhibition would enhance oxygen radical-mediated injury of the
glomerular capillary thereby worsening the degree of proteinuria
Fig. 5. (A) Changes in glomerular iNOS expression (222 bp sequence), assessed using RNase protection assay, in response to treatment of animals
with immune injury and controls with the cyclooxygenase inhibitor indomethacin or the 5-lipoxygenase inhibitor MK-0951. Lane R: riboprobe. Lanes
1-6 show iNOS mRNA levels in total RNA of glomeruli isolated from rats that received: non-immune serum (lane 1), anti-GBM serum (lane 2),
non-immune serum 1 MK-0957 (lane 3), anti-GBM serum 1 MK-0957 (lane 4), non-immune serum 1 indomethacin (lane 5), and anti-GBM serum
1 indomethacin (lane 6). (B) Changes in rat ribosomal protein L19 mRNA (used as internal standard) assessed in parallel with iNOS mRNA using the
RNase protection assay in glomeruli from rats that received anti-GBM serum, anti-GBM serum 1 MK-0857, or anti-GBM serum 1 indomethancin.
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as noted in our studies (Fig. 1). In the same vein, one would
expect that the enhanced iNOS expression induced by cyclooxy-
genase or 5-lipoxygenase inhibition (Fig. 5A), would ameliorate
proteinuria. Such an effect was not observed (Fig. 1). The reasons
are not clear. We do not know whether the enhanced iNOS
expression in animals treated with indomethacin or with the
5-lipoxygenase inhibitor, MK-0857, resulted in enhanced iNOS
enzyme activity and NO synthesis. If the enhanced iNOS expres-
sion resulted in increased NO production within nephritic glomer-
uli, then amelioration of proteinuria could occur provided that
NO does not interact with superoxide to generate peroxynitrite
(ONOO2). Peroxynitrite is a potent cell membrane oxidant and
may promote cell injury thereby offsetting the expected beneficial
effect of NO. As infiltrating activated macrophages produce super-
oxide, formation of peroxynitrite is quite likely thereby worsening the
glomerular capillary injury. Thus, to provide an explanation for the
lack of a beneficial effect of the enhanced iNOS expression following
cyclooxygenase or 5-lipoxygenase inhibition on proteinuria, one
would have to measure changes in iNOS enzyme activity and in
glomerular production of NO and peroxynitrite. In addition,
Fig. 6. Platelet deposition in glomeruli of a
nephritic animal (A) and of a nephritic animal
that received the inducible nitric oxide synthase
(iNOS) inhibitor, L-N6-(1-iminoethyl) lysine
(L-NIL), prior to injection of the anti-GBM
serum (B). Intraglomerular platelet deposits
were detected by immunofluorescence micros-
copy using an anti-rat platelet antibody.
Table 1. Glomerular infiltration by macrophages assessed by
enumeration of ED1 (1) cells per glomerulus in 25 to 30 glomeruli of
representative animals in each experimental group
Control 3.2 6 1.1
Anti-GBM Ab 25 6 2.6
L-NIL 1 anti-GBM Ab 23 6 1.8
Indomethacin 1 anti-GBM Ab 29 6 2.0
MK-0951 1 anti-GBM Ab 22 6 1.8
Treatment with L-NIL, or indomethacin, or MK-0951 had no effect on
the extent of macrophage infiltration in glomeruli compared to that in
glomeruli of animals with anti-GBM antibody injury alone.
Definitions are: Control, administration of non-immune rabbit serum.
Anti-GBM Ab, administration of immune rabbit serum containing anti-rat
GBM antibody. Abbreviations are in the Appendix.
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assessment of the net effect of iNOS expression on proteinuria
may become more apparent at later points (that is, days) of the
glomerular immune injury rather than at the early point (24 hr)
chosen in the present studies. The worsening in proteinuria
observed in response to cyclooxygenase inhibition in our studies
(Fig. 2) is consistent with observations by other investigators in
the model of anti-GBM nephritis [25]. In those studies, adminis-
tration of indomethacin increased urine protein excretion and
glomerular leukotriene synthesis [26].
In summary, our studies provide the first demonstration that
regulatory interactions occur between the arachidonic acid path-
ways and the L-arginine:NO pathway in glomerular immune
injury. Inducible nitric oxide synthase activation, possibly through
sustained generation of NO, partially accounts for the enhanced
synthesis of the arachidonate cyclooxygenation products PGE2
and PGI2 and for the enhanced synthesis of the arachidonate
lipoxygenation products 5-HETE and 15-HETE and LTB4. On
the other hand, arachidonate cyclooxygenation and 5-lipoxygen-
ation eicosanoids down-regulate iNOS expression. These obser-
vations provide evidence for feedback regulatory interactions
between the L-arginine:NO and the arachidonate cyclooxygen-
ation and lipoxygenation pathways in glomerulonephritis. Thus,
iNOS-derived NO may “drive” synthesis of certain prostaglandins
(PGE2, PGI2) and leukotrienes (5-HETE, 15-HETE, and LTB4),
while certain prostaglandins and leukotrienes may inhibit iNOS
expression. The observations are of apparent importance in
understanding the pathobiology of glomerulonephritis and in
considering novel therapeutic strategies based on inhibition of
iNOS or of specific eicosanoids.
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APPENDIX
Abbreviations used in this article are: COX, cyclooxygenase; GBM,
glomerular basement membrane; HETE, hydroxyeicosatetraenoic acids;
HPLC, high pressure liquid chromatography; iNOS, inducible nitric oxide
synthase; 5-LO, 5-lipoxygenase; LT, leukotrienes; N-NIL, L-N6-(1-imino-
ethyl) lysine; NO, nitric oxide; LTB4, arachidonate 5-lipoxygenation
product; PCR, polymerase chain reaction; PG, prostaglandin; RT-PCR,
reverse transcription-polymerase chain reaction; Tx, thromboxane.
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